Compare Inovio Pharmaceuticals Inc (INO) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs 22nd Century Group Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: Inovio Pharmaceuticals Inc is far larger — about 180.5× 22nd Century Group Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and 22nd Century Group Inc for 32 Days on average.
| INO | XXII | |
|---|---|---|
Market Cap | $112.19M | $621.67K |
Volume | 3,201,278 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $2.65 | $483.00 |
52-Week Low | $0.66 | $0.80 |
Typical Hold Time | 43 Days | 32 Days |
Enterprise Value | $83.51M | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
